Onpattro

Alnylam CEO, ‘disappointed’ with FDA’s Onpattro rejection, pivots to the future
Alnylam CEO, ‘disappointed’ with FDA’s Onpattro rejection, pivots to the future
Pharma Voice
Alnylam
Pharma CEOs
Yvonne Greenstreet
FDA
Onpattro
Flag link:
5 FDA decisions to watch in the fourth quarter
5 FDA decisions to watch in the fourth quarter
BioPharma Dive
FDA
Alnylam
Onpattro
ATTR amyloidosis
Vertex Pharmaceuticals
CRISPR Therapeutics
exa-cel
Bluebird Bio
Zynteglo
sickle cell disease
Bristol Myers Squibb
2seventy bio
Abecma
Multiple Myeloma
Amgen
Lumakras
non-small cell lung cancer
Pfizer
estrasimod
ulcerative colitis
Flag link:
Despite FDA doubts, Alnylam wins expert backing for Onpattro expansion into rare heart disease
Despite FDA doubts, Alnylam wins expert backing for Onpattro expansion into rare heart disease
Fierce Pharma
Alnylam
FDA
Onpattro
ATTR-CM
Flag link:
FDA Questions Efficacy of Alnylam’s Drug in ATTR-CM Ahead of Adcomm Meeting
FDA Questions Efficacy of Alnylam’s Drug in ATTR-CM Ahead of Adcomm Meeting
BioSpace
Alnylam
FDA
ATTR-CM
Onpattro
Flag link:
5 FDA decisions to watch in the third quarter
5 FDA decisions to watch in the third quarter
BioPharma Dive
FDA
SAGE Therapeutics
Biogen
zuranolone
Eisai
Leqembi
Sanofi
AstraZeneca
nirsevimab
Iveric Bio
Zimura
Alnylam
Onpattro
Flag link:
Alnylam’s Onpattro succeeds in open-label ATTR cardiomyopathy extension
Alnylam’s Onpattro succeeds in open-label ATTR cardiomyopathy extension
Clinical Trials Arena
Alnylam Pharmaceuticals
Onpattro
clinical trials
transthyretin amyloidosis with cardiomyopathy
Flag link:
AstraZeneca stays on course to challenge Alnylam with 66-week rare disease data
AstraZeneca stays on course to challenge Alnylam with 66-week rare disease data
Fierce Biotech
AstraZeneca
Ionis Pharmaceuticals
aplontersen
Alnylam
Onpattro
clinical trials
ATTRv-PN
Flag link:
Alnylam's new Onpattro data raise fresh doubts in heart disease fight against Pfizer: analyst
Alnylam's new Onpattro data raise fresh doubts in heart disease fight against Pfizer: analyst
Fierce Pharma
Alnylam
Onpattro
Pfizer
ATTR-CM
Flag link:
Alnylam details anticipated results from heart disease drug trial
Alnylam details anticipated results from heart disease drug trial
BioPharma Dive
Alnylam
clinical trials
Onpattro
transthyretin amyloidosis with cardiomyopathy
Flag link:
Alnylam drug succeeds in heart study, setting stage for FDA filing and showdown with Pfizer
Alnylam drug succeeds in heart study, setting stage for FDA filing and showdown with Pfizer
MedCity News
Alnylam
Pfizer
Onpattro
hATTR
Flag link:
Alnylam reveals longer wait for anticipated drug trial results
Alnylam reveals longer wait for anticipated drug trial results
BioPharma Dive
Alnylam
earnings
clinical trials
Onpattro
Flag link:
Alnylam shoots for the heart
Alnylam shoots for the heart
EP Vantage
Alnylam
Onpattro
ATTR amyloidosis
Flag link:
How a surprise finding made an Alnylam study one of biotech’s most ‘polarizing’ trials
How a surprise finding made an Alnylam study one of biotech’s most ‘polarizing’ trials
BioPharma Dive
Alnylam
clinical trials
Onpattro
transthyretin amyloid cardiomyopathy
Flag link:
SFNP 2022 – Alnylam takes heart from its Onpattro follow-on
SFNP 2022 – Alnylam takes heart from its Onpattro follow-on
EP Vantage
Alnylam
vutrisiran
Onpattro
hereditary ATTR amyloidosis
Flag link:
AAN 2021 – Helios backs Alnylam’s sunny forecasts
AAN 2021 – Helios backs Alnylam’s sunny forecasts
EP Vantage
Alnylam
AAN
vutrisiran
Onpattro
hATTR amyloidosis
Flag link:
Alnylam Pharmaceuticals and Gen sign distribution agreement in Turkey for ONPATTRO (patisiran)
Alnylam Pharmaceuticals and Gen sign distribution agreement in Turkey for ONPATTRO (patisiran)
Pharmaceutical Business Review
Alnylam
RNAi
Gen
Onpattro
Turkey
hATTR amyloidosis
Flag link:
Alnylam's Onpattro back in the game against Ionis, thanks to NICE U-turn
Alnylam's Onpattro back in the game against Ionis, thanks to NICE U-turn
Fierce Pharma
Ionis
Tegsedi
RNAi
Alnylam
Onpattro
NICE
Flag link:
Can Pfizer Leap Over the Competition With This Potential Blockbuster?
Can Pfizer Leap Over the Competition With This Potential Blockbuster?
Motley Fool
Pfizer
Vyndamax
tafamidis
ATTR
Alnylam
Onpattro
Akcea Therapeutics
Tegsedi
Eidos Therapeutics
AG10
Flag link:
Alnylam posts strong Onpattro sales as competition heats up
Alnylam posts strong Onpattro sales as competition heats up
Biopharma Dive
Alnylam
Onpattro
earnings
Flag link:
2 Biotechs With Big Dates in April
2 Biotechs With Big Dates in April
Motley Fool
Alnylam
EASL
Intercept Pharmaceuticals
Onpattro
givosiran
NASH
Ocaliva
Flag link:

Pages